Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Quick facts

Phase 2 pipeline

• 5-fluorouracil,leucovorin,panitumumab · Oncology
  This combination uses 5-fluorouracil and leucovorin as chemotherapy agents to inhibit thymidylate synthase and enhance fluorouracil cytotoxicity, while panitumumab blocks EGFR signaling to prevent tumor cell growth and survival.
• capecitabine, oxaliplatin, irinotecan and bevacizumab
• Oxaliplatin, 5-fluorouracil,leucovorin,panitumumab
• Palonosetron, Dexamethasone, Carboplatin, Paclitaxel, Olanzapine
• Pembrolizumab, Etoposide, Cisplatin or Carboplatin
• PF03446962
• Plasma collection
• Promensil · Other

Phase 1 pipeline

• adjuvant HIPEC
• Lanreotide and Metformin
• Methadone PCA

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Fondazione IRCCS Istituto Nazionale dei Tumori, Milano portfolio CI brief
• Fondazione IRCCS Istituto Nazionale dei Tumori, Milano pipeline updates RSS

Related

• Sector hub: All tracked pharma companies